Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Planchard, David; Besse, Benjamin; J.M. Groen, Harry; M.S. Hashemi, Sayed; Mazières, Julien; Min Kim, Tae; Quoix, Élisabeth; Souquet, Pierre‐Jean; Barlési, Fabrice; S. Baik, Christina; C. Villaruz, Liza; J. Kelly, Ronan; Zhang, Shirong; Tan, Monique; Gasal, Eduard; Santarpia, Libero; E. Johnson, Bruce

doi:10.1016/j.jtho.2021.08.011

Public

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Published in Journal of Thoracic Oncology • Aug 26, 2021

Authors:

David Planchard

Benjamin Besse

Harry J.M. Groen

Abstract

INTRODUCTION: Dabrafenib plus trametinib was found to have robust antitumor activity in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated survival analysis of a phase 2 study (NCT01336634) with a minimum of 5-year follow-up and updated genomic data. METHODS: Pretreated (co...

Subject

Dabrafenib

Medicine

Trametinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!